Tenecteplase contraindications

Revision as of 20:56, 6 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Tenecteplase}} {{CMG}}; {{AE}} {{SS}} ==Contraindications== TNKase therapy in patients with acute myocardial infarction is contraindicated in the following situat...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Tenecteplase
TNKASE® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Tenecteplase
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Contraindications

TNKase therapy in patients with acute myocardial infarction is contraindicated in the following situations because of an increased risk of bleeding (seeWARNINGS):

  • Active internal bleeding
  • History of cerebrovascular accident
  • Intracranial or intraspinal surgery or trauma within 2 months
  • Intracranial neoplasm, arteriovenous malformation, or aneurysm
  • Known bleeding diathesis
  • Severe uncontrolled hypertension[1]

References

  1. "TNKASE (TENECTEPLASE) KIT [GENENTECH, INC.]". Retrieved 6 February 2014.

Template:WikiDoc Sources